Kajian Interaksi Obat pada Resep Polifarmasi Dokter Spesialis Dalam Periode April 2024 di Salah Satu Apotek di Kota Bandung

Annisa Maulida Azzahra; Yasmiwar Susilawati

doi:10.55606/jig.v2i3.3123

Authors

Annisa Maulida Azzahra Universitas Padjadjaran
Yasmiwar Susilawati Universitas Padjadjaran

DOI:

https://doi.org/10.55606/jig.v2i3.3123

Keywords:

Polypharmacy, Drug Interactions, Pharmacists

Abstract

Drug interaction is a change in the effect of a drug due to the presence of other drugs taken simultaneously, which will cause a decrease in the therapeutic effect of the drug and toxicity in the body can increase. Changes in drug effects due to drug interactions vary greatly between individuals because they are influenced by various factors such as dose, drug levels in the blood, route of drug administration, drug metabolism, duration of therapy and patient characteristics. The potential for drug interactions can occur, one of which is in patients who take a large number of drugs simultaneously or Polypharmacy. Therefore, this study is related to the problem of drug interactions that occur due to Polypharmacy Prescriptions from internal medicine specialists at One of the Pharmacies in Bandung City which really needs to be considered, especially by a pharmacist. The results can be concluded that there are 22 drug interactions originating from 69 prescriptions with details of 10 minor interactions, 11 moderate interactions, and 1 major interaction. This shows that of the 69 prescriptions that have been studied, only 31.88% have interactions with minor, moderate, and major categories.

Downloads

Download data is not yet available.

References

Agustin, O. A., & Fitrianingsih, F. (2021). Kajian interaksi obat berdasarkan kategori signifikansi klinis terhadap pola peresepan pasien rawat jalan di Apotek X Jambi. Electronic Journal Scientific of Environmental Health and Disease, 1(1), 1–10. https://doi.org/10.22437/esehad.v1i1.10759

Ansari, J. (2010). Drug interaction and pharmacist. Journal of Young Pharmacists, 2(3), 326–331. https://doi.org/10.4103/0975-1483.66807

Constantia, N., Aulia, H., & Subarnas, A. (2024). Analysis of potential interactions between drugs in polypharmacy prescriptions in Bandung City pharmacies. Abstrak Pendahuluan, September 2023, 94–99.

García, J., Vaz, M., & Poggi, M. (2015). Estimated prevalence of contraindicated, severe and moderate interactions in ambulatory patients with polypharmacy in a healthcare provider in Uruguay. Clinical Therapeutics, 37(8), e145. https://doi.org/10.1016/j.clinthera.2015.05.416

Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L., Seibel, M. J., McLachlan, A. J., Cumming, R. G., Handelsman, D. J., & Le Couteur, D. G. (2012). Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 65(9), 989–995. https://doi.org/10.1016/j.jclinepi.2012.02.018

Herdaningsih, S., Muhtadi, A., Lestari, K., & Annisa, N. (2016). Potential of drug-drug interaction in polypharmacy prescription: Retrospective study on a drugstore in Bandung. Indonesian Journal of Clinical Pharmacy, 5(4), 288–292. https://doi.org/10.15416/ijcp.2016.5.4.288

Isnenia, I. (2020). Penggunaan non-steroid antiinflamatory drug dan potensi interaksi obatnya pada pasien muskuloskeletal. Pharmaceutical Journal of Indonesia, 6(1), 47–55. https://doi.org/10.21776/ub.pji.2020.006.01.8

Kurniawati, F., Yasin, N. M., Dina, A., Atana, S., & Hakim, S. N. (2021). Kajian adverse drug reactions terkait interaksi obat di bangsal rawat inap Rumah Sakit Akademik UGM. Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 10(4), 297–308. https://doi.org/10.22146/jmpf.60228

Mahamudu. (2017). Kajian potensi interaksi obat antihipertensi. Pharmacon: Jurnal Ilmiah Farmasi – Unsrat, 6(3), 1–9.

Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety, 13(1), 57–65. https://doi.org/10.1517/14740338.2013.827660

Montané, E., Barriocanal, A., Isern, I., Parajon, T., & Costa, J. (2009). Multiple drug interactions-induced serotonin syndrome: A case report. Journal of Clinical Pharmacy and Therapeutics, 34(4), 485–487. https://doi.org/10.1111/j.1365-2710.2009.01023.x

Parulian, L. P., Listyanti, E., Hati, A. K., & Sunnah, I. (2019). Analisis hubungan polifarmasi dan interaksi obat pada pasien rawat jalan yang mendapat obat hipertensi di RSP Dr. Ario Wirawan periode Januari-Maret 2019. Indonesian Journal of Pharmacy and Natural Product, 2(2), 79–86. https://doi.org/10.35473/ijpnp.v2i2.280

Rahmawati, F., Handayani, R., & Gosal, V. (2006). Kajian retrospektif interaksi obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta. Majalah Farmasi Indonesia, 17(4), 177–183.

Siddiqua, A., Kareem Abdul, W., Ayan, S., Al Azm, L., & Ali, S. (2018). Antecedents of patients’ trust in pharmacists: Empirical investigation in the United Arab Emirates. International Journal of Pharmacy Practice, 26(1), 63–72. https://doi.org/10.1111/ijpp.12359

Viktil, K. K., Blix, H. S., Moger, T. A., & Reikvam, A. (2007). Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. British Journal of Clinical Pharmacology, 63(2), 187–195. https://doi.org/10.1111/j.1365-2125.2006.02744.x

Williams, D., & Feely, J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 41(5), 343–370. https://doi.org/10.2165/00003088-200241050-00003

Wola, D., Wijayahadi, N., Sobirin, M. A., & Kresnoadi, E. (2022). Toxicity, side effects, and furosemide interactions in therapy of heart failure patients (Systematic Review). Diponegoro Medical Journal (Jurnal Kedokteran Diponegoro, 11(4). https://doi.org/10.14710/dmj.v11i3.33706

Yuniar, Y., Ramadhiani, A. R., Asyifa, D., Ade Putri, W. K., & Apriliana, W. S. (2022). Potensi interaksi obat pada pasien COVID-19 terkonfirmasi dengan komorbid di Bangsal Ogan RSUP Dr. Mohammad Hoesin Palembang periode April-Juni 2021. Majalah Farmaseutik, 18(1), 43. https://doi.org/10.22146/farmaseutik.v18i1.71910

Zarowitz, B. J., Stebelsky, L. A., Muma, B. K., Romain, T. M., & Peterson, E. L. (2005). Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy, 25(11), 1636–1645. https://doi.org/10.1592/phco.2005.25.11.1636

Zia, A., Kamaruzzaman, S. B., & Tan, M. P. (2015). Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgraduate Medicine, 127(3), 330–337. https://doi.org/10.1080/00325481.2014.996112